Kezar Life Sciences, Inc.
KZR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.33 | -1.75 | 240.94 | -170.45 |
| FCF Yield | -15.15% | -1.21% | -0.13% | -0.05% |
| EV / EBITDA | -5.73 | -69.06 | -717.12 | -1,664.71 |
| Quality | ||||
| ROIC | -68.07% | -50.23% | -24.20% | -25.13% |
| Gross Margin | 0.00% | 84.77% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 0.80 | 0.86 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 11.04% | -38.12% | -41.33% | -15.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.32 | 0.17 | 0.29 | 0.92 |
| Interest Coverage | -56.88 | -67.89 | -60.05 | -343.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.60 |
| Cash Conversion Cycle | -1,281.36 | -2,705.70 | -884.49 | 114.09 |